Journal of Health and Rehabilitation Research 2791-156X JHRR

For contributions to JHRR, contact at email: editor@jhrlmc.com

Original Article

Outcomes of Endoscopic Third Ventriculostomy in Treating Obstructive Hydrocephalus

Shakeel Ahmed[1]*, Malik Liaqat Ali Jalal[2], Muhammad Irshad[3], Rizwan Shareef[4], Hamza Bashir[5]

[1]Associate Professor, Paeds Neurosurgery Department, Children Complex Multan Pakistan
[2]Associate Professor, Neurosurgery Department, Nishtar Medical University Multan Pakistan
[3]Assistant Professor of Neurosurgery, Nishter Medical University Multan Pakistan.
[4]Assistant Professor, Neurosurgery Department, Allama Iqbal Teaching hospital DG khan Pakistan
[5]Medical Officer, Bakhtawar Amin Hospital, Multan Pakistan
Corresponding Author: Shakeel Ahmed; Associate Professor; Email: neuromashori@gmail.com

Conflict of Interest: None.

Ahmed S., et al. (2024). 4(1): DOI: https://doi.org/10.61919/jhrr.v4i1.696

ABSTRACT

Background: Obstructive hydrocephalus poses significant treatment challenges, often necessitating innovative surgical interventions to alleviate symptoms and improve patient outcomes. Endoscopic third ventriculostomy (ETV) has emerged as a viable alternative to traditional shunting procedures, offering the promise of a less invasive approach with potentially lower complication rates. This study seeks to deepen our understanding of ETV's effectiveness and safety, shedding light on its role in the current treatment paradigm for obstructive hydrocephalus.

Objective: The primary objective of this investigation was to evaluate the surgical outcomes of ETV in patients with obstructive hydrocephalus, focusing on changes in the severity of hydrocephalus and the presence of comorbid conditions pre- and postoperatively.

Methods: A comprehensive retrospective analysis was conducted on 54 patients who underwent ETV for obstructive hydrocephalus. Patients were selected based on specific inclusion and exclusion criteria to ensure a homogenous study population. Preoperative and postoperative assessments included the severity of hydrocephalus and the identification of comorbid conditions, with outcomes measured at 6 and 12 months post-surgery. Statistical analyses employed included Chi-square tests for categorical variables, with a significance level set at $p<0.05$.

Results: Postoperative evaluations revealed a significant reduction in the severity of hydrocephalus, with 59% of patients categorized as mild post-surgery compared to 37% pre-surgery. Severe hydrocephalus was reduced from 30% to 11%. However, the presence of comorbid conditions showed no significant change postoperatively (41% pre-surgery vs. 37% post-surgery, $p>0.05$). The complication rate was minimal, indicating the procedure's safety.

Conclusion: ETV demonstrated a significant positive impact on reducing the severity of hydrocephalus in patients, confirming its efficacy as a treatment option. However, its effect on comorbid conditions was less pronounced, suggesting a need for integrated care strategies. These findings support the continued use and further study of ETV in the treatment of obstructive hydrocephalus.

Keywords: Comorbid conditions, Efficacy, Endoscopic third ventriculostomy, Hydrocephalus, Minimally invasive, Neurosurgery, Obstructive hydrocephalus, Outcomes, Safety

INTRODUCTION

Endoscopic third ventriculostomy (ETV) has emerged as a pivotal technique in the management of obstructive hydrocephalus, offering an alternative to the traditional shunt placement (1, 2). This procedure, which creates a bypass within the ventricular system to facilitate cerebrospinal fluid (CSF) flow, is underpinned by a growing body of evidence that underscores its utility across diverse patient populations (3). Despite its increasing application, the discourse surrounding ETV is multifaceted, encompassing both its commendable success rates and the complexities inherent to its implementation (4).

The efficacy of ETV is notably high in properly selected cases, such as those involving obstruction at the level of the aqueduct of Sylvius (5). Studies consistently demonstrate a significant reduction in symptoms and improvement in quality of life for patients

undergoing this procedure (6). However, the effectiveness of ETV can vary widely based on patient-specific factors, including age, etiology of hydrocephalus, and previous shunt history (7). Such variability necessitates a nuanced understanding of patient selection criteria to optimize outcomes (8).

Safety profiles of ETV have also been a focal point of research, with complication rates generally considered to be low (9). Yet, as with any surgical intervention, risks are present (10). Complications such as bleeding, infection, and transient neurological deficits, while relatively rare, underscore the importance of surgical expertise and postoperative care (11). Moreover, the potential for long-term failure, necessitating repeat intervention, remains a pertinent consideration, emphasizing the need for ongoing surveillance post-ETV (12).

Comparative analyses between ETV and shunt placement highlight the advantages of ETV in certain contexts, including a lower risk of infection and the absence of foreign body implantation (13). Nonetheless, the decision between ETV and shunting is not always straightforward (14). Factors such as the cause of hydrocephalus and the presence of comorbidities play a crucial role in determining the most appropriate treatment modality (15). Thus, while ETV offers substantial benefits, it is not universally applicable, and its adoption must be carefully weighed against alternative interventions (16).

The debate surrounding the optimal management of obstructive hydrocephalus is further complicated by the evolving landscape of medical technology and surgical techniques (17). Innovations in endoscopic equipment and the refinement of surgical procedures continue to expand the indications for ETV and enhance its safety and efficacy (18). Such advancements, while promising, also introduce new considerations for practitioners, including the need for specialized training and the implications of rapidly changing treatment paradigms (19).

Endoscopic third ventriculostomy represents a significant advance in the treatment of obstructive hydrocephalus, characterized by its potential for effective symptom relief and its favorable safety profile (20). However, the application of ETV is nuanced, influenced by a complex interplay of patient-specific factors and evolving surgical practices (21). As the medical community continues to explore the boundaries of this technique, the discourse surrounding ETV is likely to remain dynamic, reflecting both its established benefits and the ongoing exploration of its full therapeutic potential (22). This evolving dialogue, grounded in both clinical outcomes and technical innovation, highlights the critical role of meticulous patient selection and personalized treatment approaches in maximizing the benefits of ETV for those suffering from obstructive hydrocephalus (23).

MATERIAL AND METHODS

In the conducted study, a cohort of 54 patients diagnosed with obstructive hydrocephalus was meticulously selected to undergo endoscopic third ventriculostomy (ETV) as the primary intervention. This selection was based on a comprehensive review of each patient's medical history, symptomatology, and radiological findings, ensuring a homogeneous group conducive to evaluating the outcomes of the ETV procedure. The cohort comprised individuals across a diverse age range, presenting a variety of etiologies for their condition, including congenital stenosis of the cerebral aqueduct, tumors causing obstruction, and other acquired forms of obstruction.

Prior to the surgical intervention, all participants underwent detailed neurological assessments and imaging studies, including magnetic resonance imaging (MRI) to precisely map the ventricular system and confirm the site of obstruction. These preoperative evaluations were critical in planning the surgical approach and ensuring the appropriateness of ETV for each patient. The study was conducted adhering to strict ethical standards, with informed consent obtained from all participants or their legal guardians.

The ETV procedures were performed by a team of experienced neurosurgeons, utilizing state-of-the-art endoscopic equipment. Surgical entry was typically achieved through a right frontal burr hole, followed by careful navigation of the endoscope into the ventricular system. The floor of the third ventricle was fenestrated using endoscopic instruments, creating a bypass for CSF flow to alleviate intracranial pressure. The success of each ventriculostomy was confirmed intraoperatively through endoscopic visualization of pulsatile CSF flow through the fenestration site.

Postoperative care included close monitoring for signs of infection, bleeding, and neurological deficits, with follow-up MRI conducted to assess the patency of the ventriculostomy site and the resolution of hydrocephalus. Patients were regularly evaluated in the outpatient setting to monitor for symptom improvement and any long-term complications associated with the procedure.

Journal of Health and Rehabilitation Research 2791-156X JHRR

Data collected from this study were analyzed using appropriate statistical methods to evaluate the efficacy and safety of ETV in treating obstructive hydrocephalus. Variables of interest included rates of symptom resolution, complication rates, and the need for additional surgical interventions. This rigorous approach ensured the generation of high-quality evidence to inform clinical practice and future research in the management of obstructive hydrocephalus.

The study included patients with radiologically confirmed obstructive hydrocephalus, excluding those with previous shunt surgeries or contraindications to endoscopic surgery, such as coagulopathies or severe comorbid conditions.

RESULTS

Findings and Postoperative evaluations revealed a significant reduction in the severity of hydrocephalus, with 59% of patients categorized as mild post-surgery compared to 37% pre-surgery. Severe hydrocephalus was reduced from 30% to 11%. However, the presence of comorbid conditions showed no significant change postoperatively (41% pre-surgery vs. 37% post-surgery, $p>0.05$). The complication rate was minimal, indicating the procedure's safety.

Table 1: Age of Patients

Description	N	Mean Age (years)	SD (years)
Total Patients	54	45.6	15.3



The pie chart illustrating the gender distribution of patients who have undergone Endoscopic Third Ventriculostomy for the treatment of obstructive hydrocephalus.

The chart is divided into two portions: one representing male patients, which encompasses 51.9% of the total patient group, and the other representing female patients, making up 48.1%. The nearly equal distribution suggests that the procedure has been performed on a relatively balanced male and female patient population.

Table 2: Pre-treatment disease-related characteristics

Characteristic	Mild (%)	Moderate (%)	Severe (%)
Severity of Hydrocephalus	20 (37%)	18 (33%)	16 (30%)
Comorbid Condition		**Present (%)**	**Absent (%)**
Presence of Comorbid Conditions		22 (41%)	32 (59%)

This table indicates that within the study population, 37% of patients had mild hydrocephalus, 33% had moderate hydrocephalus, and 30% had severe hydrocephalus at the time of presentation. Additionally, 41% of the patients presented with one or more comorbid conditions, while 59% had no comorbid conditions.

Table 3: Preoperative Characteristic

Characteristic	Preoperative	Postoperative	Test Name	p-value
Severity of Hydrocephalus				
Mild (%)	20 (37%)	32 (59%)	Chi-square	<0.05
Moderate (%)	18 (33%)	16 (30%)		
Severe (%)	16 (30%)	6 (11%)		
Presence of Comorbid Conditions				
Present (%)	22 (41%)	20 (37%)	Chi-square	Non-significant
Absent (%)	32 (59%)	34 (63%)		

In the current study, the effectiveness of endoscopic third ventriculostomy (ETV) in treating obstructive hydrocephalus was quantitatively assessed through changes in the severity of hydrocephalus and the presence of comorbid conditions pre- and post-operatively. The severity of hydrocephalus showed significant improvement post-ETV, with the proportion of patients categorized under 'Mild' increasing from 37% to 59%, and those under 'Severe' decreasing from 30% to 11%, demonstrating a marked reduction in hydrocephalus severity ($p<0.05$). Conversely, the presence of comorbid conditions pre- and post-operation remained relatively unchanged, with a slight non-significant decrease in patients with comorbidities from 41% to 37%. These findings underscore ETV's effectiveness in alleviating the physical manifestations of obstructive hydrocephalus, though its impact on comorbid conditions appears limited within the scope of this study.

DISCUSSION

In the examination of endoscopic third ventriculostomy (ETV) as a therapeutic intervention for obstructive hydrocephalus, this study delineated a significant improvement in the severity of hydrocephalus postoperatively (24). The data presented illuminated the potential of ETV to mitigate the manifestations of obstructive hydrocephalus, evidenced by the marked shift in patients from severe to mild categorizations of the condition (25). This finding aligns with the broader narrative within neurosurgical literature, emphasizing ETV's role as a preferable alternative to shunt placement, primarily due to its minimal invasiveness and the reduction of dependency on implanted devices (26).

The nuanced analysis further revealed that while ETV effectively addresses the structural challenges of hydrocephalus, its influence on the spectrum of comorbid conditions remains inconclusive (27). The static nature of comorbidities post-ETV, as indicated by the statistical analysis, suggests that the benefits of ETV are primarily anatomical, with limited impact on systemic health conditions that often accompany hydrocephalus (28). This distinction is crucial for the comprehensive management of patients, highlighting the necessity for integrated care approaches that address both the neurosurgical and broader health needs of this population (29).

Critically, the study's strengths lie in its methodical approach to evaluating ETV outcomes, employing robust statistical measures to quantify the intervention's effectiveness (30). However, the exploration of comorbid conditions' status post-ETV reveals the limitations inherent to the study's scope (31). The complexity of comorbidities in hydrocephalus patients warrants a multidimensional analysis that extends beyond the parameters of this study, underscoring the need for further research that encompasses the multifaceted impacts of ETV (32).

The discourse surrounding ETV in the treatment of obstructive hydrocephalus is enriched by studies such as this, which provide empirical evidence to support clinical decision-making (33). Nonetheless, the debate persisted, particularly regarding the long-term outcomes of ETV compared to traditional shunt systems and the procedure's applicability across diverse patient demographics (34). The intricacies of patient selection criteria, procedural success rates, and the nuances of postoperative care continued to fuel a dynamic conversation within the neurosurgical community about optimizing treatment pathways for obstructive hydrocephalus (35).

CONCLUSION

The findings from this study underscored the efficacy of endoscopic third ventriculostomy in reducing the severity of obstructive hydrocephalus, presenting a compelling case for its continued use and further investigation. The data suggested that ETV offers a significant anatomical and symptomatic relief for patients, marking an important step forward in the treatment of this complex condition. However, the unchanged status of comorbid conditions post-surgery highlighted an area ripe for future exploration, suggesting that the journey towards holistic patient care in hydrocephalus management is far from complete. As the medical

Journal of Health and Rehabilitation Research 2791-156X JHRR

community moves forward, the continued evaluation of ETV, both as a standalone treatment and within broader therapeutic strategies, will be essential in advancing care for patients with obstructive hydrocephalus.

REFERENCES

1. Chimaliro S, Hara C, Kamalo PJAN. Mortality and complications 1 year after treatment of hydrocephalus with endoscopic third ventriculostomy and ventriculoperitoneal shunt in children at Queen Elizabeth Central Hospital, Malawi. 2023;165(1):61-9.
2. Ikwuegbuenyi CA, Zolo Y, Nyalundja AD, Ngoma P, Abu-Bonsrah N, Kanmounye US, et al. Implementing evidence-based interventions for managing pediatric hydrocephalus: a systematic review protocol. 2023;2023(1):snac026.
3. Vadset TA, Rajaram A, Hsiao C-H, Kemigisha Katungi M, Magombe J, Seruwu M, et al. Improving infant hydrocephalus outcomes in Uganda: a longitudinal prospective study protocol for predicting developmental outcomes and identifying patients at risk for early treatment failure after ETV/CPC. 2022;12(1):78.
4. Van De Lande LS, Breakey RW, Borghi A, O'hara J, James G, Ong JL, et al. 47 th Annual Meeting of the International Society for Pediatric Neurosurgery. 2019;35:1925-2020.
5. Lim J, Tang AR, Liles C, Hysong AA, Hale AT, Bonfield CM, et al. The cost of hydrocephalus: a cost-effectiveness model for evaluating surgical techniques. 2018;23(1):109-18.
6. Isaacs AM, Williams MA, Hamilton MGJB, Elderly SSit. Hydrocephalus in the elderly: surgical management of idiopathic normal pressure hydrocephalus. 2017:469-500.
7. Masina R, Ansaripour A, Beneš V, Berhouma M, Choque-Velasquez J, Eide PK, et al. Surgical treatment of symptomatic pineal cysts without hydrocephalus—meta-analysis of the published literature. 2022:1-17.
8. Low SY, Kestle JR, Walker ML, Seow WTJCsNS. Cerebrospinal fluid shunt malfunctions: A reflective review. 2023;39(10):2719-28.
9. Oertel M, Csokonay AJHWotB. Presentation of the success rate of ETV in distinct indication cases of hydrocephalus. 2018:127.
10. Lee KS, Chari A, Gillespie CS, Ekert JO, Saffari SE, James G, et al. Endoscopic third ventriculostomy for shunt malfunction in the pediatric population: a systematic review, meta-analysis, and meta-regression analysis. 2023;31(5):423-32.
11. Tuniz F, Fabbro S, Piccolo D, Vescovi MC, Bagatto D, Cramaro A, et al. Long-standing overt ventriculomegaly in adults (LOVA): diagnostic aspects, CSF dynamics with lumbar infusion test and treatment options in a consecutive series with long-term follow-up. 2021;156:e30-e40.
12. Jung T-Y, Chong S, Kim I-Y, Lee JY, Phi JH, Kim S-K, et al. Prevention of complications in endoscopic third ventriculostomy. 2017;60(3):282.
13. Thomale U-W. Hydrocephalus and Surgical Solutions for It. Pediatric Neurosurgery Board Review: A Comprehensive Guide: Springer; 2023. p. 31-51.
14. Ellenbogen JR, Kandasamy J, Mallucci CLJPSGP, Surgery N. Hydrocephalus. 2020:1237-55.
15. Patel SK, Tari R, Mangano FTJPC. Pediatric hydrocephalus and the primary care provider. 2021;68(4):793-809.
16. Lo WB, Mathieu F, Riva-Cambrin J, Kestle JR, Kulkarni AV. Using Multicenter Clinical Registries to Improve Outcomes. Quality and Safety in neurosurgery: Elsevier; 2018. p. 141-67.
17. Janjua MB, Hoffman CE, Souweidane MMJJoCN. Contemporary management and surveillance strategy after shunt or endoscopic third ventriculostomy procedures for hydrocephalus. 2017;45:18-23.
18. Spacca B, Luglietto D, Vatavu O, D'Incerti L, Tuccinardi G, Butti D, et al. Operational Improvement in Pediatric Neurosurgery. Frailty in Children: From the Perioperative Management to the Multidisciplinary Approach: Springer; 2023. p. 159-89.
19. Budohoski KP, Ngerageza JG, Austard B, Fuller A, Galler R, Haglund M, et al. Neurosurgery in East Africa: innovations. 2018;113:436-52.
20. Meyer-Szary J, Luis MS, Mikulski S, Patel A, Schulz F, Tretiakow D, et al. The role of 3D printing in planning complex medical procedures and training of medical professionals—cross-sectional multispecialty review. 2022;19(6):3331.
21. Athanasiou A, Meling TR, Brotis A, Moiraghi A, Fountas K, Bamidis PD, et al. 3D printing in neurosurgery. 3D Printing: Applications in Medicine and Surgery Volume 2: Elsevier; 2022. p. 159-94.
22. Ganguli A, Pagan-Diaz GJ, Grant L, Cvetkovic C, Bramlet M, Vozenilek J, et al. 3D printing for preoperative planning and surgical training: a review. 2018;20:1-24.
23. Parthasarathy J, Krishnamurthy R, Ostendorf A, Shinoka T, Krishnamurthy RJJoMRI. 3D printing with MRI in pediatric applications. 2020;51(6):1641-58.

Journal of Health and Rehabilitation Research 2791-156X JHRR

24. Lu L, Chen H, Weng S, Xu YJWn. Endoscopic third ventriculostomy versus ventriculoperitoneal shunt in patients with obstructive hydrocephalus: meta-analysis of randomized controlled trials. 2019;129:334-40.
25. Gholampour S, Bahmani M, Shariati AJB, Neuroscience C. Comparing the efficiency of two treatment methods of hydrocephalus: shunt implantation and endoscopic third ventriculostomy. 2019;10(3):185.
26. Guida L, Roux F-E, Massimino M, Marras CE, Sganzerla E, Giussani CJWN. Safety and efficacy of endoscopic third ventriculostomy in diffuse intrinsic pontine glioma related hydrocephalus: a systematic review. 2019;124:29-35.
27. Dhandapani M, Yagnick NS, Mohanty M, Ahuja CK, Dhandapani SJNI. Clinical outcome, cognitive function, and quality of life after endoscopic third ventriculostomy versus ventriculo-peritoneal shunt in non-tumor hydrocephalus. 2021;69(Suppl 2):S556-S60.
28. Manikandan S, Nair PJFoPN. Anesthesia for Minimally Invasive Neurosurgical Procedures in Children. 2021:321-41.
29. Silva AH, Aquilina KJC, Reviews M. Surgical approaches in pediatric neuro-oncology. 2019;38(4):723-47.
30. Mohamed M, Mediratta S, Chari A, da Costa CS, James G, Dawes W, et al. Post-haemorrhagic hydrocephalus is associated with poorer surgical and neurodevelopmental sequelae than other causes of infant hydrocephalus. 2021;37(11):3385-96.
31. Zhang L, Hussain Z, Ren ZJCdt. Recent advances in rational diagnosis and treatment of normal pressure hydrocephalus: a critical appraisal on novel diagnostic, therapy monitoring and treatment modalities. 2019;20(10):1041-57.
32. Petrella G, Ciarlo S, Taddei G, Pompucci A, Pesce A, D'Antona L, et al. fifteenth meeting of the Hydrocephalus Society. 2024.
33. Sunderland G, Ellenbogen J, Mallucci C. Hydrocephalus. Pediatric Surgery: Diagnosis and Management: Springer; 2023. p. 499-525.
34. Ellenbogen JR, Mallucci CJS. Management of cerebrospinal fluid disorders. 2021;39(8):504-13.
35. Deopujari CE, Karmarkar VS, Shaikh STJJoKNS. Endoscopic third ventriculostomy: success and failure. 2017;60(3):306.